OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Survey taken by pharma and CRO executives evaluates attributes of large datasets.
While real-world data has shown the potential to transform the clinical trials industry, uptake and usage of real-world data has not met expectations. What drives the uptake and usage of real-world data? In this blog, we look at the attributes or characteristics of the raw data. More-and more companies are acquiring expensive and large datasets that allow for sophisticated analysis. What are the attributes of these datasets that drive real-world data adoption?
To assess this question, we surveyed 133 pharma & CRO executives. We asked them to rate the importance of various data attributes if they were selecting a real-world dataset. The attributes we considered were the ability to tailor the data structure and data dictionary and the availability of analytics support from the data provider, chart reviews, retrospective longitudinal data, prospective longitudinal data, and biomarker data.
While the ability to handle longitudinal data stands out, all of the data attributes are all ranked fairly high and are all close to each other, suggesting the importance of the data and the difficulties that executives have in one attribute above all the others. Our respondents have expectations for the data. What about their satisfaction with these data attributes?
Our respondents had low satisfaction relative to the importance of the data attributes. None of the satisfaction ratings across the functions came up to the importance. The average satisfaction level was a mean of 1.2 points below the rated importance. While biomarker data had the lowest satisfaction, we emphasize that is not far below the highest rated data attribute. None of the attributes excelled in their satisfaction scores.
We also examined the gaps between the importance and satisfaction scores to prioritize improvement efforts.
The best opportunity to improve the performance (i.e. The Return on Data) of data is enhancing the reliability of data, followed by cost and responsiveness. Organizations need data that will work every time and be able to respond to organizational needs at a reasonable cost.
Some of these issues relate not just to the data, but also the intermediaries (analytic software, vendors, and consultants) that convert raw data to information. We consider this in the next blog.
For more information on RWD, view this Pharm Exec Roundtable from March 2022.
Michael Howley, PA-C, MBA, PhD & Peter Malamis, MBA